跳至主要内容
临床试验/EUCTR2015-002802-34-Outside-EU/EEA
EUCTR2015-002802-34-Outside-EU/EEA进行中(未招募)不适用

Multicentre study to evaluate the efficacy and safety of a liquid formulation of recombinant growth hormone, Omnitrope® 3.3mg/mL, in the treatment of pre-pubertal children of small stature suffering from somatotropin deficiency (GH) – phase IIIb

Sandoz SAS0 个研究点目标入组 100 人开始时间: 2015年7月3日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Sandoz SAS
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Small stature due to growth hormone deficiency
  • Age: girls of under 10 years of age and boys of under 12
  • Height = -2 SD or < -1.5 SD with slow Growth Rate (GR < -1 SD or < 4 cm/year)
  • Weight in line with statural age ± 2SD
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 100
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Prior or current treatment with GH
  • Presence of an active tumour; a lapse of at least 12 months will be required since tumour treatment
  • Current corticosteroid treatment other than substitution treatment or use of an inhaled corticosteroid
  • Insulin-dependent diabetes (according to the WHO definition), or other chronic, severe disease
  • Small stature for other reasons than growth hormone deficiency
  • Peutz-Jeghers syndrome or a family history of colon cancer

研究者

发起方
Sandoz SAS

相似试验

已完成
不适用
Multicentre clinical study of the efficacy and safety of INHaled INSulin aerosol in the treatment of type 2 diabetesType 2 diabetesNutritional, Metabolic, EndocrineDiabetes
ISRCTN81772352Chuangxinhui Biotech Venture Capital Co., Ltd (China)252
进行中(未招募)
不适用
Multicenter clinical study on the efficacy and safety with extensive and repeated injections of cultured (human) autologous hair follicle dermal sheath cup cells on male and female pattern hair loss
JPRN-jRCTb032200148Harada Kazutoshi36
进行中(未招募)
不适用
A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension Phase
EUCTR2005-004637-17-DEALLERGAN LTD650
进行中(未招募)
1 期
A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension Phase
EUCTR2005-004637-17-GBALLERGAN LTD650
已完成
不适用
A multicentre study to determine the efficacy and patient acceptability of scalp cooling in the prevention of docetaxel-induced hair lossCancer
ISRCTN00283877eiden University Medical Centre (LUMC) (The Netherlands)260